Clinical Trial Update: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on KQ-2003 CAR-T cell therapy for relapsed or refractory multiple myeloma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• KQ-2003

Snippet

Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN